Monopar Therapeutics Stock Net Income
| MNPR Stock | USD 0.73 0.07 10.18% |
Monopar Therapeutics fundamentals help investors to digest information that contributes to Monopar Therapeutics' financial success or failures. It also enables traders to predict the movement of Monopar Stock. The fundamental analysis module provides a way to measure Monopar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Monopar Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -9.5 M | -10 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Net Loss | -8.4 M | -8.8 M | |
| Net Loss | (0.61) | (0.64) | |
| Net Income Per E B T | 0.90 | 0.79 |
Monopar | Net Income |
Monopar Therapeutics Company Net Income Analysis
Monopar Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Monopar Therapeutics Net Income | (8.4 M) |
Most of Monopar Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Monopar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Monopar Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Monopar Therapeutics is extremely important. It helps to project a fair market value of Monopar Stock properly, considering its historical fundamentals such as Net Income. Since Monopar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Monopar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Monopar Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Monopar Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Monopar Therapeutics reported net income of (8.4 Million). This is 102.46% lower than that of the Biotechnology sector and 112.0% lower than that of the Health Care industry. The net income for all United States stocks is 101.47% higher than that of the company.
Monopar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monopar Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics of similar companies.Monopar Therapeutics is currently under evaluation in net income category among related companies.
Monopar Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Monopar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Monopar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Monopar Therapeutics' value.| Shares | Wells Fargo & Co | 2023-12-31 | 37.0 | Fmr Inc | 2023-09-30 | 0.0 | Jpmorgan Chase & Co | 2023-12-31 | 0.0 | Two Sigma Securities, Llc | 2023-12-31 | 0.0 | Windsor Advisory Group, Llc | 2023-12-31 | 0.0 | Hrt Financial Llc | 2023-12-31 | 0.0 | Renaissance Technologies Corp | 2023-12-31 | 48.1 K | Vanguard Group Inc | 2023-12-31 | 45.2 K | Geode Capital Management, Llc | 2023-12-31 | 41.2 K | Millennium Management Llc | 2023-12-31 | 29.3 K | Gerber Llc | 2023-12-31 | 28 K |
Monopar Fundamentals
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 4.25 M | ||||
| Shares Outstanding | 17.45 M | ||||
| Shares Owned By Insiders | 52.35 % | ||||
| Shares Owned By Institutions | 1.55 % | ||||
| Number Of Shares Shorted | 150.01 K | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 2.44 X | ||||
| EBITDA | (8.83 M) | ||||
| Net Income | (8.4 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 8.41 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 11.52 M | ||||
| Total Asset | 7.35 M | ||||
| Retained Earnings | (60.21 M) | ||||
| Working Capital | 5.58 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
| Net Asset | 7.35 M |
About Monopar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Monopar Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Monopar Therapeutics' short interest history, or implied volatility extrapolated from Monopar Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Monopar Therapeutics Piotroski F Score and Monopar Therapeutics Altman Z Score analysis. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for Monopar Stock analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Monopar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Return On Assets (0.54) | Return On Equity (1.07) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.